Our lead clinical development program, ANPD001, is an autologous dopaminergic neuronal precursor cell (DANPC) therapy being studied in Parkinson’s disease (PD).

(ANPD001) has received IND clearance and Fast Track designation from the U.S. Food and Drug Administration (FDA), and is currently under investigation in the ASPIRO Phase 1/2a trial for the treatment of Parkinson’s disease.

Our clinical development programs encompass multiple candidates for cell replacement therapy within the Central Nervous System (CNS).

We are also investigating several candidates for the treatment of both sporadic and genetic forms of Parkinson’s disease, as well as additional candidates targeted in the CNS.

Strong Pipeline Focused on Parkinson’s Disease

Additional opportunities to leverage platform with other cell types

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.